Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors

Abstract Bispecific antibodies exhibit proven clinical benefit, and many bispecifics are currently in clinical development for oncology. Cytokine release syndrome (CRS) is a common clinical adverse effect observed following CD3‐based bispecific dosing. However, the pathophysiology of CRS is not full...

Full description

Bibliographic Details
Main Author: Jared Weddell
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:CPT: Pharmacometrics & Systems Pharmacology
Online Access:https://doi.org/10.1002/psp4.12928